Skip NavigationSkip to Content
Return Return to Search Results

Discovery of potent and selective PROTACs for the protein kinase LZK for the treatment of head and neck cancer

  1. Author:
    Katerji,Meghri
    Bergman, Knickole L
    Lindberg, Eric
    Rubin,Maxine
    Funk, Amy L
    Woodroofe, Carolyn C
    Nyswaner, Katherine
    Karpinska, Kamila
    Serwa, Remigiusz
    Marusiak, Anna
    Swenson, Rolf E
    Brognard,John

  2. Author Address

    Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD, 21702, USA., Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, MD, 20850, USA., Laboratory of Molecular OncoSignalling, IMol Polish Academy of Sciences, Warsaw, Poland., Proteomic Core Facility, IMol Polish Academy of Sciences, Warsaw, Poland., Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, MD, 20850, USA. Electronic address: rolf.swenson@nih.gov., Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD, 21702, USA. Electronic address: john.brognard@nih.gov.,
    1. Year: 2025
    2. Date: Mar 27
    3. Epub Date: 2025 03 27
  2. Journal: The Journal of Biological Chemistry
    1. Pages: 108452
  4. Type of Article: Article
  5. Article Number: 108452
  1. Abstract:

    Leucine zipper-bearing kinase (LZK) is overexpressed in 20% of head and neck squamous cell carcinoma (HNSCC) cases and has emerged as a promising therapeutic target in this cancer subtype. LZK promotes HNSCC survival and proliferation by stabilizing c-MYC and GOF-p53 in kinase-dependent and -independent manners, respectively. Herein, we developed a new series of LZK degraders utilizing proteolysis-targeting chimera (PROTAC) technology by modulating the linker region or LZK warhead of LZK-targeting PROTAC-21A, previously developed by our lab. Among the 27 PROTACs synthesized and tested, PROTAC 17 was found to be the most potent, degrading LZK at 250 nM and suppressing HNSCC viability at 500 nM. In summary our lead PROTAC effectively targeted LZK for proteasomal degradation and inhibited oncogenic activity in HNSCC cell lines with amplified LZK. Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.jbc.2025.108452
  3. PMID: 40157536
  4. PII : S0021-9258(25)00301-1

Library Notes

  1. Fiscal Year: FY2024-2025
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel